Reckitt Benckiser hurt as rivals steal heroin march
Tuesday 26 February 2013
Shares in Reckitt Benckiser took a tumble yesterday on news that its competitors will be able to make heroin-dependency drugs to compete with the consumer goods group.
Reckitt had been trying to slow down competitors' plans to make rival drugs after it lost US patent protection for its heroin-dependency treatment drug Suboxone in 2009. But yesterday investors reacted to news that the US Food and Drug Administration had rejected Reckitt's petition to force rivals to take more precautions with the drugs packaging.
Reckitt's shares took a hit and ended 135p lower at 4,381p. Not only has Reckitt lost its plea, but two generic drug makers have been given the go-ahead to enter the Suboxone tablet market with drugs that contain its key buprenorphine ingredient.
The Dettol-to-Durex maker introduced a film-strip version of Suboxone that is less likely to be taken accidentally by children. It will stop producing Suboxone in tablet form next month. It had hoped packaging for the opiate substitute would become regulated to make it more expensive for rivals to produce.
But the FDA decided that data presented by Reckitt did not necessitate the regulation that the company had suggested, which had included educational campaigns and child-resistant packaging.
Reckitt had previously pointed out that there is evidence of a rise in abuse of the medicine by children, who are able to open packets of drugs in tablet form.
It said yesterday it was "disappointed" by the FDA's decision. But it added that it will "continue to work with the FDA on safety enhancements", and remains "committed to maintaining its own high level standards for safety, including the use of child resistant, unit-dose packaging". Jefferies' Alex Howson said the entry of rivals into the market has been "a well-flagged risk for Reckitt" but some investors had forgotten these risks – until yesterday.
About 90 per cent of Suboxone tablet business and 70 per cent of the film business could be lost to generics, and Jefferies estimates 2013 Suboxone profits could reduce by 17 per cent to £382m.
However, analysts think the share sell-off in the Slough-based company has been overdone.
Deutsche Bank's Harold Thompson thinks Reckitt's repeated communication to "expect the worst on generic entry" means the profit impact on the group could be more measured than the investors think. Mr Thompson points out that more than 95 per cent of Reckitt's group profits are not related to US Suboxone tablets.
Analysts expect the group's household goods division, which includes brands such as Clearasil, Cillit Bang and Strepsils, will perform well this year.
Mr Thompson said he thinks the shares are still worth buying while Mr Howson added: "There will soon be "an attractive entry point [for the shares], given that the core business has seen substantial improvement of late."
He thinks "a major positive catalyst" would be the sale of the pharmaceuticals business altogether, as the market would "reward the improved visibility".
Presents unwrapped, turkey gobbled... it's time to relax
- 1 Jennifer Lawrence scores first UK top 40 single with Hunger Games track 'The Hanging Tree'
- 2 Shia LaBeouf claims he was raped during #IAMSORRY art installation performance
- 4 Scientists predict green energy revolution after incredible new graphene discoveries
Sean Abbott: Messages of support flood in for bowler after death of Phil Hughes
Dr Lam Hoe Yeoh: Voyeur doctor jailed for eight years after using network of hidden cameras to film patients, colleagues and friends on the toilet
Kim Jong-un 'in dire need of allies' within his own government as younger sister appointed to senior role
Scientists predict green energy revolution after incredible new graphene discoveries
Michael Buerk wishes he killed Jimmy Savile when he had the chance - by pushing him overboard a cruise ship
Obama: The only people with the right to object to immigration are Native Americans
Ukip says babies born to immigrants in the UK should be classed as migrants – which would include Nigel Farage’s own children
The young are the new poor: Sharp increase in number of under-25s living in poverty, while over-65s are better off than ever
Tamir Rice: 12-year-old boy playing with fake gun dies after being shot by Ohio police
Ukip mocked after mistaking Westminster Cathedral – for a mosque
Plebgate: Andrew Mitchell’s reputation in tatters as judge rules he used the word ‘pleb’
iJobs Money & Business
Excellent Package: Austen Lloyd: EAST ANGLIA - SENIOR SOLICITOR LEVEL ROLE** -...
£Attractive Package: Citifocus Ltd: Prestigious asset management house seeks a...
£Negotiable: Citifocus Ltd: This is a varied role focusing on the firm's mutua...
£90000 - £140000 per annum + benefits: h2 Recruit Ltd: Are you a high achievin...